To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Invitae filed for Chapter 11 ...
Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...
A new survey released today shows 73 percent of Americans are aware of genetic testing for hereditary cancers – a significant increase over just a few years ago. Previous research found that in 2010 ...
SAN FRANCISCO, Jan. 30, 2024 /PRNewswire/ -- Invitae (NVTA) (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (BBIO), a commercial-stage ...
Horizon Therapeutics plc in partnership with Invitae Corporation announced a new urea cycle disorder (UCD) genetic testing programme designed to speed diagnosis and enable physicians to offer genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results